Xiao Changting, Dash Satya, Stahel Priska, Lewis Gary F
From the Division of Endocrinology and Metabolism, Department of Medicine and Department of Physiology, Banting and Best Diabetes Centre, University of Toronto, Ontario, Canada.
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1776-1781. doi: 10.1161/ATVBAHA.117.309705. Epub 2017 Jul 27.
Insulin administered directly into the brain acutely suppresses hepatic glucose production and triglyceride-rich lipoprotein (TRL) secretion in rodents. In addition, intranasally administered insulin, which selectively raises cerebrospinal fluid insulin concentration, suppresses hepatic glucose production in humans; however, its effect on TRL secretion in humans has not previously been examined. In this study, we examined whether intranasal insulin, administered at a dose that has previously been shown to suppress hepatic glucose production, modulates TRL particle secretion by the liver and intestine in humans.
Nine healthy, normolipidemic, and normoglycemic men participated in a study consisting of 2 randomized study arms. Subjects received intranasal lispro insulin (40 IU) or placebo. Because intranasal insulin results in a rapid and transient increase in systemic insulin concentration after administration, we matched systemic insulin concentrations in the 2 study arms by infusing lispro insulin intravenously for 30 minutes together with intranasal placebo administration. Apo (apolipoprotein) B100-containing (hepatically derived) and apoB48-containing (intestinally derived) TRL lipoprotein particle turnover were measured for the ensuing 10 hours under pancreatic clamp conditions and constant fed state, using stable isotope enrichment techniques and multicompartmental modeling. Under these experimental conditions, no significant effects of intranasal insulin versus placebo on TRL apoB100 or B48 concentrations, fractional catabolic rates, or production rates were observed.
Insulin delivered intranasally at a dose that has been shown to raise cerebrospinal fluid insulin concentration and suppress hepatic glucose production does not affect TRL particle production by the liver and intestine in healthy men.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT03141827.
直接注入脑内的胰岛素可急性抑制啮齿动物的肝葡萄糖生成及富含甘油三酯脂蛋白(TRL)分泌。此外,经鼻给予胰岛素可选择性提高脑脊液胰岛素浓度,从而抑制人体的肝葡萄糖生成;然而,此前尚未研究其对人体TRL分泌的影响。在本研究中,我们探讨了以先前已证实可抑制肝葡萄糖生成的剂量经鼻给予胰岛素,是否会调节人体肝脏和肠道的TRL颗粒分泌。
9名健康、血脂正常且血糖正常的男性参与了一项包含2个随机研究组的研究。受试者接受经鼻赖脯胰岛素(40 IU)或安慰剂。由于经鼻给予胰岛素后会导致全身胰岛素浓度迅速短暂升高,我们通过在经鼻给予安慰剂的同时静脉输注赖脯胰岛素30分钟,使两个研究组的全身胰岛素浓度相匹配。在胰腺钳夹条件和持续进食状态下,使用稳定同位素示踪技术和多室模型,在随后的10小时内测量含载脂蛋白(apo)B100(源自肝脏)和含apoB48(源自肠道)的TRL脂蛋白颗粒周转率。在这些实验条件下,未观察到经鼻胰岛素与安慰剂相比对TRL apoB100或B48浓度、分解代谢率或生成率有显著影响。
以已证实可提高脑脊液胰岛素浓度并抑制肝葡萄糖生成的剂量经鼻给予胰岛素,对健康男性肝脏和肠道的TRL颗粒生成没有影响。